Hilleman Laboratories Officially Opens US$20 Million Facility in Singapore to Bolster Resilience in Vaccine Manufacturing

Hilleman Laboratories Partners A*STAR to Develop a Nipah Virus Vaccine using Circular RNA Technology

Hilleman Laboratories to Develop A Thermostable Second-Generation Zaire Ebolavirus Vaccine In Collaboration with MSD

SK bioscience and Hilleman Laboratories to Co-develop New Vaccine Platforms

International Vaccine Institute Signs Memorandum of Understanding with Hilleman Laboratories to Advance Vaccine R&D and Manufacturing for Safe, Effective, and Affordable Vaccines in Low-and Middle-Income Countries

Hilleman Laboratories breaks ground on pilot cGMP facility for vaccine development

Hilleman Laboratories establishes pilot manufacturing facility for vaccine development in Singapore with support from Singapore Economic Development Board